Mizuho Securities analyst Difei Yang maintained a Buy rating on Aerie Pharma (AERI) today and set a price target of $77. The company’s shares opened today at $47.04.
Yang observed:
“We are including weekly IQVIA Scripts for Rhopressa below. For the week ended 02/22/2019, Rhopressa TRx increased +0.5% to 5,522 from 5,495 the prior week; and Rhopressa NRx decreased -0.1% to 2,375 from 2,378 the prior week. Note that the week ended 02/22/2019 has only four workdays due to the President’s Day. We provide Scripts data for informative purposes only. We believe investors should focus on longer-term demand trends vs. weekly scripts fluctuations.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 18.1% and a 50.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
Aerie Pharma has an analyst consensus of Strong Buy, with a price target consensus of $80.71, implying a 71.6% upside from current levels. In a report issued on February 21, Oppenheimer also assigned a Buy rating to the stock with a $64 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $74.75 and a one-year low of $32.18. Currently, Aerie Pharma has an average volume of 655.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan.
